Matsuzaki 2005.

Methods	CCT conducted in Japan during the 2003‐2004 influenza season Response to influenza vaccine in children with cancer who are receiving chemotherapy is compared with that of children with cancer off chemotherapy
Participants	44 children with various types of malignancies, of whom 18 were receiving chemotherapy and 26 had finished chemotherapy for 1 to 60 months. Age 1 to 18 years
Interventions	Trivalent inactivated split (KAKETSUKEN) influenza vaccine subcutaneously, containing 30 µg HA per ml of each of the following strains: A/New Caledonia/20/99 (H1N1), A/Panama/2007/99, B/Shangdong/7/97. Participants received two doses, 2 to 4 weeks apart at doses of 0.2 ml for children aged 1 to < 6 years, 0.3 ml for those aged 6 to < 13 years and 0.5 ml for those 13 years of age or older, according to recommendations in Japan
Outcomes	(1) Seroconversion (defined as four‐fold rise in antibody titre) after two vaccinations (2) Achieving protective antibody titre (HI antibody titre ≥ 40) after two vaccinations (3) Adverse effects
Notes	No numbers pertaining to adverse effects stated